Vasopressin vs. norepinephrine for vasoplegic shock after cardiac surgery

emcrit.org November 25, 2016

Patients in the VANISH trial treated with vasopressin had a lower incidence of renal failure requiring hemodialysis. However, this was a secondary endpoint which seemed to contradict the primary endpoint (defined as a milder degree of kidney injury). New data may clarify this controversy.

AKI renal failure stroke surgery trial vasopressin

Fluid Personalization and Vasopressor Decisions in Early Sepsis Management

Fluid Personalization and Vasopressor Decisions in Early Sepsis Management

AKI Risk Factors in ICU Patients Using Colistin

AKI Risk Factors in ICU Patients Using Colistin

Haloperidol vs. Placebo in ICU Patients with Delirium

Haloperidol vs. Placebo in ICU Patients with Delirium

Ilofotase Alfa Doesn’t Improved Survival Among Critically Ill Patients with SA-AKI

Ilofotase Alfa Doesn’t Improved Survival Among Critically Ill Patients with SA-AKI

The Advanced Ventilator Book

COVID-19 Airway Management and Ventilation Strategy for Critically Ill Older Patients

State of the Art Techniques in Critical Care Echocardiography

Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill

Seven Signs of Life: Stories from an Intensive Care Doctor

Evidence-Based Practice of Palliative Medicine

Advanced Perioperative Crisis Management

Sepsis Management: PIRO and MODS

Extracorporeal Life Support for Adults

COVID-19 Airway Management and Ventilation Strategy for Critically Ill Older Patients

Critical Care: A New Nurse Faces Death, Life, and Everything in Between